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The Clinical Implications of Blood Adiponectin
in Cardiometabolic Disorders
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Adipose tissue is now accepted by the scientific and medical community to be a genuine endocrine organ,
in addition to its classical role as an energy store. Adiponectin is one of the many adipocytokines that are
secreted almost exclusively by adipose tissue. Alteration in blood adiponectin concentrations has been
linked to many human diseases in numerous cross-sectional and prospective studies. In this review, we de-
scribe briefly the biological effects of adiponectin as revealed by basic scientific investigations. We also
summarize the principles of blood adiponectin assays. Overall, lower blood adiponectin concentration is
found in subjects with obesity, type 2 diabetes mellitus, dyslipidemia, and hypertension. These medical
conditions are components of the metabolic syndrome and major risk factors for accelerated atherosclero-
sis. Plasma adiponectin levels are also expected to be lower in subjects with cardiovascular diseases, such as
coronary artery disease, ischemic stroke and peripheral artery disease. Congestive heart failure (CHF) and
cardiac arrhythmia are common end points in cardiovascular diseases. Surprisingly, higher blood adiponectin
levels are frequently reported to predict mortality associated with CHF. Few human data regarding
adiponectin and cardiac arrhythmia are available. Higher blood adiponectin level has been documented
only in atrial fibrillation. We also summarize data on the role of the high molecular weight (HMW) iso-
forms of adiponectin and the effects of clinical treatment on the levels of total or HMW adiponectin.
Whether adiponectin is a risk marker or a risk factor for the diseases reviewed in this article, and in many
other human diseases, and their detailed pathogenic links awaits further investigation. [J Formos Med Assoc
2009;108(5):353–366]
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diabetes, dyslipidemia, heart failure, hypertension, metabolic syndrome, obesity, 
peripheral vascular diseases, stroke
Fat Hormone
Obesity has become a global epidemic in children
and adults, and is considered to be the root cause
of many metabolic diseases that we face today.1
Through advancing our understanding of the
pathogenesis of obesity, we no longer view adipose
tissue as a simple fat reservoir for energy storage.
Instead, adipose tissue is now considered an en-
docrine organ, actively regulating energy balance
and many other physiological functions.2 The
crucial evidence leading to the formation of this
concept was the discovery of leptin.
More than 40 years ago, monogenic obesity and
diabetes mouse models, obese (ob) and diabetes
(db), were identified.3,4 These two models were
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demonstrated to harbor two spontaneous recessive
mutant alleles. Although they share similar syn-
dromes of hyperphagic obesity with prominent
diabetes and endocrine dysfunction, they are in
fact caused by two different genes.5 The parabiosis
experiments conducted by Coleman et al pro-
vided insight into the underlying mechanisms.6,7
Connecting the blood circulation of ob/ob mice
with that of wild-type or db/db mice led to signif-
icant weight loss in the ob/ob animals, while con-
necting the circulation of db/db mice with that of
ob/ob or wild-type mice exerted no effect on the
db/db animals. These findings indicate that a cir-
culating factor that causes weight loss is missing
in ob/ob mice, while possibly the receptor for the
factor is lacking in db/db mice. This circulating
factor, a 16-kDa peptide hormone, was later dis-
covered by positional cloning of the ob gene in
mice in 1994.8 Since the factor promoted weight
loss in ob/ob mice, it was termed leptin, which was
derived from “leptos”, the Greek for thin.9 Soon
thereafter, the leptin receptor was also cloned in
1995.10 The leptin receptor is exactly what is miss-
ing in db/db mice. Leptin therefore became the first
example of the fat hormones, or the so-called
adipocytokines or adipokines, which are produced
mainly by the adipose tissues and have significant
systemic effects. A comprehensive review of leptin
is beyond the scope of the present article. Readers
interested in this are advised to read some recent
reviews.11,12
Among the adipocytokine family, adiponectin,
the second example of the fat hormones, has drawn
much attention recently from researchers seeking
its biological and clinical implications.13
Basic Science of Adiponectin
In the mid-1990s, four independent Japanese or
American groups isolated adiponectin (also known
as Acrp30/adipoQ/apM1/GBP28) by using diverse
techniques.14–17 Adiponectin is secreted primarily
from mature adipocytes. It is a 30-kDa molecule
that contains a 20-residue amino-terminal signal
sequence, a variable region, a collagenous domain
and a carboxy-terminal globular domain.18 Adi-
ponectin circulates in the blood in higher-order
structural forms and at a relatively high concentra-
tion compared with the other peptide hormones.17
These multimeric forms identified by different
methods (such as gel filtration chromatography,
gel electrophoresis or Western blotting) include
trimeric (low molecular weight, LMW), hexam-
eric (middle molecular weight, MMW), and even
high molecular weight (HMW) complexes.17,19
Although some studies have proposed that the
ratio of the HMW to other forms may serve as a
better indicator of metabolic disorders,19–22 the
majority of studies that have linked adiponectin
with metabolic diseases have used assays for total
adiponectin.
One of the effects of adiponectin on energy
balance is mediated by an increase in β-oxidation
of fatty acids in skeletal muscles.23 In mice, admin-
istration of the protease-generated globular head
domain of adiponectin decreases dramatically
the level of plasma free fatty acids.23 It has also
been demonstrated in mice that injection of
adiponectin can reduce plasma glucose levels and
improve insulin sensitivity.24,25 The repression of
hepatic glucose output is accomplished through
lowering the mRNA expression of hepatic glu-
coneogenic enzymes, such as phosphoenolpyru-
vate carboxykinase and glucose-6-phosphatase.26
Besides, studies that have utilized adiponectin
knockout mice have shown that these mice are
inclined to diet-induced insulin resistance and
glucose intolerance.27,28 In ob/ob mice, transgenic
adiponectin keeps the animals from developing
insulin resistance and hyperglycemia.29
Substantial evidence in animal studies has
shown that adiponectin may also exert advanta-
geous effects on the cardiovascular system. In
adiponectin knockout mice, hypertension in-
duced by treatment with high-salt diet can be al-
leviated by adenovirus-delivered adiponectin.30
In adiponectin-deficient mice, pressure overload
induces concentric cardiac hypertrophy and mor-
tality.31 Moreover, adiponectin supplementation
reduces lipid accumulation on the vascular
wall,29,32 attenuates neointimal proliferation33
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and thrombus formation,34 and improves angio-
genic repair.35
In 2003, Yamauchi et al identified adiponectin
receptors 1 and 2 (AdipoR1 and AdipoR2).36 These
receptors, predicted to contain seven transmem-
brane domains, are mainly found in skeletal
muscle, liver, and pancreatic β cells. AdipoR1 is
expressed extensively in skeletal muscle, while
AdipoR2 is distributed mostly in liver. Additionally,
functional differences between AdipoR1 and
AdipoR2 have been demonstrated.37 While
AdipoR1 is involved in the AMP-dependent pro-
tein kinase (AMPK) signaling pathway, AdipoR2
is associated more with the peroxisome prolifera-
tor activator receptor (PPAR)-α pathway.37 Besides
the above-mentioned pathways, adiponectin stim-
ulates various signaling pathways. For example,
adiponectin activates p38 mitogen-activated pro-
tein kinase (MAPK) and c-jun N-terminal kinase
(JNK) in osteoblasts, which enhances cell prolif-
eration and differentiation.38 In human umbilical
vein endothelial cells, adiponectin inhibits the
activation of IκB kinase (IKK) induced by tumor
necrosis factor (TNF)-α or high glucose, which
supports its anti-inflammatory role.39 In vascular
endothelial cells, adiponectin stimulates produc-
tion of nitric oxide through phosphatidylinositol-
3-kinase-dependent pathways.40 The regulation
of adiponectin expression and its post-receptor
signaling has been discussed in some recent review
articles.13,41
Implications of Plasma Adiponectin in
Human Cardiometabolic Disorders
Assays for blood adiponectin
For determination of adiponectin levels in periph-
eral circulation, many immunometric systems,
such as radioimmunoassay (RIA) and ELISA, have
been developed and have been available com-
mercially for many years. The pioneer develop-
ment of ELISA was achieved by Arita et al from
Matsuzawa’s laboratory and has had many appli-
cations in clinical research.42 For ELISA measure-
ment of adiponectin, the adiponectin multimers
in the biological samples are converted to
monomers or dimers by treatment with SDS at
high temperature or at pH 3.0–3.5.42,43 The cali-
bration curve is obtained by using recombinant
adiponectin or dimeric adiponectin as a calibra-
tion standard.42,43 If a particular molecular weight
form is of special interest, two kinds of proteinase
can be used to digest selectively the adiponectin
multimers.43 Protease A (from Aspergillus oryzae),
which digests LMW adiponectin can be utilized
in the measurement of MMW and HMW forms.
In contrast, protease K (from Tritirachium album),
which digests LMW and MMW adiponectin can
be applied to the evaluation of the HMW form.
Thus, by combination, the concentration levels of
each form may be obtained. For interested readers,
a more comprehensive discussion can be found
in some recent papers.19,43–47 In the following
discussion, whenever adiponectin is mentioned,
total adiponectin is implied unless indicated
otherwise. Previous studies have shown different
results with regard to whether HMW adiponectin
complexes are the main component related to its
biological effects. This will be reviewed in this ar-
ticle. Furthermore, since the amount of the HMW
form is so closely related to the total adiponectin
level, some authors have reported that measure-
ment of the HMW complexes does not provide
additional information.48
The association between plasma adiponectin
levels and various diseases has been demonstrated
in numerous human studies.49–51 In this review,
we will limit our discussion to human metabolic
and cardiovascular disorders. Human genetic stud-
ies of adiponectin and its receptors have also re-
vealed important implications of adiponectin in
human diseases.52–54
Plasma adiponectin and obesity
Obesity provided the first link between human
disease and plasma adiponectin levels.42 In the
very first report of ELISA for plasma adiponectin,
Arita et al demonstrated the paradoxical associa-
tion between body mass index (BMI) and plasma
adiponectin levels.42 They also showed that females
in general had higher plasma adiponectin than
Adiponectin and cardiometabolic disorders
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males. In addition, body fat distribution was found
to be influential. Intra-abdominal fat mass is more
related to adiponectin concentration than subcu-
taneous fat is.55–57 Although adiponectin has been
related closely to obesity in cross-sectional studies,
lower plasma adiponectin is unlikely to be the
cause of obesity. On the contrary, hypoadipo-
nectinemia is probably the result of obesity. In
fact, in a prospective human study, low plasma
adiponectin was not shown to predict future
body weight gain.58 Recently, we have reviewed
extensively this issue.13
Lifestyle modification to reduce body weight
has been shown to increase plasma adiponectin
levels in type 2 diabetes mellitus (T2DM) as well
as in non-diabetic subjects.59 Exercise itself, with-
out significant weight reduction, may not have a
major influence on plasma adiponectin levels.60,61
Anti-obesity pharmacotherapy may also increase
plasma adiponectin levels. Modest weight reduc-
tion supplemented with orlistat, a pancreatic li-
pase inhibitor, increases plasma adiponectin.62,63
Sibutramine, a neurotransmitter reuptake in-
hibitor, reduces weight with or without increasing
plasma adiponectin.62,64,65 Rimonabant, an endo-
cannabinoid receptor blocker, reduces weight,
improves metabolic profiles and increases plasma
adiponectin.66 Among severely obese subjects,
anti-obesity surgery results in significant weight
reduction and metabolic benefits, accompanied
by increased plasma adiponectin levels.67,68 In
contrast, contradictory results regarding the ef-
fects of liposuction on obesity-related metabolic
abnormalities and plasma adiponectin levels have
been reported.69,70 In summary, we can conclude
that any clinical measure that gives rise to signif-
icant weight reduction and improvement in in-
sulin sensitivity can, without doubt, increase the
blood concentration of adiponectin.
In more recent studies, the relationship between
obesity and different isoforms of adiponectin has
been addressed. It appears that total and HMW
adiponectin isoforms are more related to obesity
and visceral fat.71,72 However, some authors have
not observed the significance of HMW adiponectin
in obesity.73 Weight reduction also appears to 
increase total adiponectin, HMW adiponectin and
the ratio of HMW to total adiponectin.74,75
Plasma adiponectin and diabetes mellitus
The circulation levels of adiponectin are lower in
T2DM,59,76 and in insulin-resistant states.76,77 The
Pima Indians of Arizona, USA, are a special pop-
ulation that is prone to obesity and T2DM. A lon-
gitudinal study has revealed that subjects with
high adiponectin concentrations are less likely to
develop T2DM.78 Research on Japanese and other
ethnic groups has implied that lower adiponectin
levels are associated with increased future risk of
developing insulin resistance, impaired glucose
metabolism and diabetes.79–85 Reduction of HMW
adiponectin isoforms is associated with the risk
of insulin resistance and T2DM.86–89
In contrast to that in T2DM, the plasma con-
centration of adiponectin tends to be higher in
type 1 diabetes mellitus (T1DM).90–93 Even HMW
adiponectin is increased in T1DM.94 However, in
one study, the plasma adiponectin levels did not
predict the occurrence of T1DM in autoantibody-
positive relatives.95 The controversy regarding
whether the increased plasma adiponectin con-
centration is caused by or related to co-existing
microvascular complications, especially nephrop-
athy, remains unresolved.92,94,96–99
Lifestyle modification with significant weight
reduction has been shown to enhance plasma
adiponectin concentration in T2DM, as discussed
above.59,100 Treatment of T2DM with oral anti-
diabetic agents may also alter blood concentrations
of adiponectin. In general, insulin secretagogues,
including sulfonylureas and meglitinides,101,102
do not clearly increase plasma adiponectin levels,
except for glimepiride and repaglinide.103,104 The
rare exception of glimepiride might be explained
by its long-claimed insulin-mimetic or insulin-
sensitizing effects.105 However, how repaglinide in-
creases plasma adiponectin remains unknown.106
Metformin does not appear to have a major effect
on plasma adiponectin concentration in T2DM
or in polycystic ovary syndrome, even though some
studies have shown a significant increase after
treatment.102,107,108 The α-glucosidase inhibitor
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acarbose induced a small but significant rise 
in serum adiponectin in only one study.109 In
contrast, thiazolidinediones (TZDs), such as rosi-
glitazone and pioglitazone, increased plasma
adiponectin in many human studies.101,110 This is
related to their insulin-sensitizing effects via
PPARγ2 activation in the adipose tissue. It has
been shown that some of the benefits of TZDs
may be exerted mainly through improving the
levels of HMW adiponectin complexes.111,112 So
far, there have been no human studies of dipeptidyl
protease-4 inhibitor or glucagon-like peptide-1
(GLP-1)-based therapy in relation to adiponectin.
However, we believe, with its effects on body
weight, GLP-1-based therapy should more or less
increase plasma adiponectin levels. A few studies
of insulin treatment have indicated that there
might be no significant change in blood adipo-
nectin with chronic insulin treatment.113–115 Some
other studies have found acute suppressive effects
of insulin on adiponectin levels in human stud-
ies.116–119 However, others have found no effect
on plasma adiponectin levels in patients with acute
hyperinsulinemia.120
Plasma adiponectin and dyslipidemia
Low blood levels of adiponectin are also related
to dyslipidemia.77,121,122 A positive correlation has
been found between adiponectin levels and high-
density lipoprotein (HDL)-cholesterol, while an
inverse relationship with triglycerides and apolipo-
protein (Apo) B has been demonstrated.77,121–124
Furthermore, HMW adiponectin was correlated
with the decrease in large triglyceride-rich very-
low-density lipoprotein (VLDL) and in small low-
density lipoprotein (LDL), but with the increase
in large buoyant LDL particles, accompanied by
increased LDL particle size, and the increase in
large HDL and HDL particle size.125
Statins are the mainstream pharmacotherapy
for hypercholesterolemia, specifically high LDL-
cholesterol. Treatment with statins in humans
does not significantly alter plasma adiponectin
levels in general.126–129 The intestinal cholesterol
transporter inhibitor ezetimibe is available in
clinical practice for treating hypercholesterolemia.
Treatment with ezetimibe also does not alter
plasma adiponectin levels.130 Fibrates are used to
treat hypertriglyceridemia. The effects of fibrates on
plasma adiponectin are inconsistent. Some studies
have shown an adiponectin-raising effect,131,132
while others have not found any effect.133,134 One
report has suggested that fibrates do not increase
total plasma adiponectin, but rather increase the
HMW portion.135 Nicotinic acid lowers triglyc-
erides, LDL-cholesterol and raises HDL-cholesterol.
Extended-released nicotinic acid increases plasma
adiponectin, preferentially the HMW forms.136–138
Chronic treatment with acipimox, a lipolysis 
inhibitor similar to nicotinic acid, does not alter
plasma adiponectin level.139,140 However, the
acute effects of acipimox are inconsistent. One
study has shown reduced plasma adiponectin
levels,141 but another has shown no change in
plasma adiponectin concentration after acute 
administration.117
Plasma adiponectin and hypertension
The inverse relationship between adiponectin level
and blood pressure has been investigated in many
previous studies,142–145 and re-enforced recently
by a 5-year prospective study.146 Chow et al found
that hypoadiponectinemia can serve as a power-
ful predictor for future development of hyperten-
sion, even after adjustment for well-known risk
factors, including sex, age and BMI.146
Antihypertensive medication may modulate
the plasma levels of adiponectin. Thiazide di-
uretics seem to reduce plasma adiponectin lev-
els.147 Another diuretic, indapamide, also reduces
plasma adiponectin concentration.148 Beta-adren-
ergic blockers reduce or have no effect on plasma
adiponectin levels.147–149 Calcium channel blockers
increase or have no effect on plasma adiponectin
concentrations.147,149–151 Blocking the renin–
angiotensin–aldosterone system with angiotensin-
converting enzyme inhibitors or angiotensin 
receptor 1 blockers consistently increase plasma
adiponectin levels.126,147,149,152–154 Spironolactone
has also been reported to increase plasma adipo-
nectin in type 2 diabetic patients with nephro-
pathy.155 No human studies of eplerenone or
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aliskiren have been published. The α-adrenergic
blocker doxazosin has also been shown to in-
crease plasma adiponectin levels.149 Overall, the
adiponectin-raising effects of antihypertensive
agents appear to parallel their effects on insulin
sensitivity.147,149 Among these antihypertensives,
so far, only losartan has been shown to increase
total and HMW adiponectin.156
Hypoadiponectinemia is related closely to
obesity, T2DM, dyslipidemia and hypertension.
These metabolic abnormalities are not only the
key components of the metabolic syndrome, but
also the major risk factors for cardiovascular dis-
eases.77 Therefore, we will next review the relation-
ship between blood adiponectin and coronary,
cerebral and peripheral artery diseases, congestive
heart failure (CHF) and cardiac arrhythmia.
Plasma adiponectin and coronary artery
disease (CAD)
Plasma adiponectin was first shown to be lower
in patients with CAD by Ouchi et al in 1999.157
The association between low plasma adiponectin
and CAD, disease extent or outcomes has been
demonstrated not only in cross-sectional stud-
ies,157–161 but also in prospective longitudinal
follow-up studies.162–166 For example, in a follow-
up study of male health professionals, the subjects
with higher adiponectin levels had a significantly
reduced risk of myocardial infarction, even after
correction for risk factors, such as LDL and HDL
levels, BMI, history of diabetes and hyperten-
sion and high-sensitivity C-reactive protein at
baseline.167 Some other studies, however, have
not found a predictive value for future risk of
CAD.168,169 A meta-analysis has suggested a sig-
nificant association, but the effect was relatively
moderate compared with that in previous 
studies.170
HMW adiponectin is lower in men with CAD,
but not in women.171 In a follow-up study, HMW
adiponectin has been shown to predict cardio-
vascular events in men.172 HMW adiponectin is
also associated with extent of CAD in men.173
However, negative results have also been re-
ported.174–177 Whether gender is an issue or not
in this regard remains to be clarified. Further-
more, whether adiponectin plays a specific role
at certain specific stages of CAD pathogenesis
needs to be investigated more thoroughly.
Plasma adiponectin and stroke and
peripheral artery disease (PAD)
Lower blood adiponectin levels have been re-
ported to be associated with increased risk of 
ischemic stroke and increased mortality after first
stroke event.178,179 On the other hand, some other
studies have not confirmed the value of adipo-
nectin in relation to cerebrovascular events.180–182
Plasma adiponectin has also been shown to be
inversely related to PAD, estimated by ankle–
brachial index in hemodialysis patients.183 So far,
no study has addressed the role of HMW adipo-
nectin isoforms in cerebrovascular disease or
PAD. Furthermore, no human investigation of
the effects of pentoxyphylline or cilostazol, which
are commonly used in treating PAD in clinical
practice, on plasma adiponectin levels has been
reported. However, a novel selective serotonin
2A receptor antagonist, sarpogrelate, has been
investigated in non-diabetic and non-medicated
diabetic patients with PAD.184 It was shown to
enhance insulin sensitivity and increase plasma
adiponectin.
Plasma adiponectin and CHF and 
cardiac arrhythmia
The first human study regarding the role of
adiponectin in CHF was surprising.185 It showed
that high blood adiponectin was a predictor for
mortality in CHF, independent of other risk fac-
tors. It was suggested that high adiponectin in
CHF was a sign of physical wasting. Other studies
have also demonstrated that higher adiponectin
is an independent predictor for mortality and/or
hospitalization in patients with CHF.186–189 In
cross-sectional studies, patients with CHF had
higher plasma adiponectin levels and decreased
lean body mass.188,190,191 However, in a longitu-
dinal follow-up study, in which insulin resistance
was reported to be an independent risk factor for
CHF, plasma adiponectin was not a predictor for
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CHF.192 In one study that has surveyed the role of
HMW adiponectin, it was concluded that total,
rather than HMW adiponectin was valuable in
predicting mortality in CHF.193 In many studies,
plasma adiponectin level appears to parallel the
level of natriuretic peptide.185,186,188,189,191,194,195
Moreover, infusion of carperitide (a natriuretic
peptide) in CHF patients increased their plasma
total and HMW adiponectin levels.196
Cardiac arrhythmia is a common condition in
patients with cardiovascular diseases. It has been
reported that plasma adiponectin levels are higher
in chronic atrial fibrillation (AF) than in paroxys-
mal AF and controls.197 The plasma adiponectin
levels are correlated with the collagen metabo-
lism marker, carboxy-terminal telopeptide of
collagen I, but not with type III pro-collagen-N-
peptide.197 So far, there has been no report of
adiponectin with regard to ventricular arrhythmia,
syncope, fainting or sudden death.
Conclusion
Substantial evidence has revealed the significance
of adiponectin in human health and diseases.
The underlying molecular mechanisms have pro-
vided us with clues to the intricate relationship
between adiponectin and pathogenesis. Alterations
in blood adiponectin concentration seem to be a
useful biomarker for obesity, DM, dyslipidemia,
hypertension, and even subsequent cardiovascular
diseases. We summarized the relationship of blood
adiponectin with cardiometabolic disorders in this
review. The proposed natural history is depicted
in the Figure. Hypoadiponectinemia may be caused
by obesity-induced insulin resistance in the adi-
pose tissue, as previously proposed.13 Hypoadipo-
nectinemia may contribute secondarily to insulin
resistance in other peripheral tissues, such as liver
and skeletal muscle.13 As a result, T2DM, dyslipi-
demia, hypertension, metabolic syndrome and
Adiponectin and cardiometabolic disorders
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Dietary over-consumption and physical inactivity
Obesity and insulin resistance
Hypoadiponectinemia
Insulin resistance, T2DM,
dyslipidemia, hypertension, metabolic
syndrome, atherosclerosis
Compensatory or
secondary increase in
blood adiponectin
CAD, CVA, PAD,
macrovascular complications
++
−
CHF and AF,
microvascular complications
+
+
+
+
Figure. Schematic diagram depicting the proposed natural course of blood adiponectin levels in relation to cardiometa-
bolic disorders reviewed in this article. The arrows indicate the proposed time sequence and may not necessarily imply
cause–effect relationships. The “+” signs indicate a positive association. The “−” sign indicates a negative association.
Hypoadiponectinemia is proposed to be caused by obesity-induced insulin resistance in the adipose tissue.13
Hypoadiponectinemia in turn induces insulin resistance in other tissues. As the result of certain microvascular complica-
tions, such as nephropathy and CHF, the plasma levels of adiponectin may rise. T2DM = type 2 diabetes mellitus;
CAD = coronary artery disease; CVA = cerebrovascular accident; PAD = peripheral artery disease; CHF = congestive heart
failure; AF = atrial fibrillation.
accelerated atherosclerosis occur. These conditions
may lead to subsequent macro- and microvascular
complications, and CHF and arrhythmia may fol-
low. As a result of CHF, AF or nephropathy, com-
pensatory or secondary rise in blood adiponectin
may occur later (Figure). The mechanisms of this
rise in blood adiponectin levels remain unclear.
It may be caused by reduced renal clearance of
adiponectin, disease-related weight loss, or in-
creased ectopic secretion of adiponectin from the
myocardium. If the rise in blood adiponectin is
proven to be beneficial, we do not have to wait until
late clinical events occur. Non-pharmacological
and pharmacological modulations of blood adipo-
nectin levels may be promising for ameliorating
the related disorders in the earlier stages. Through
more comprehensive studies, we believe that the
true clinical value and the mystery of the patho-
genic mechanisms of adiponectin in human dis-
eases will be unraveled in the near future.
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